{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 1 of 92', 'CR845-CLIN3103', 'CARA', 'HERAPEUTICS', 'A MULTICENTER, DOUBLE-BLIND RANDOMIZED,', 'PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND', 'EFFICACY OF INTRAVENOUS CR845 IN HEMODIALYSIS PATIENTS', 'WITH MODERATE-TO-SEVERE PRURITUS, WITH A 52-WEEK', 'OPEN-LABEL EXTENSION', 'Protocol number:', 'CR845-CLIN3103', 'Phase:', '3', 'IND number:', '123140', 'EUDRACT number:', '2018-001930-17', 'Investigational Product:', 'CR845 solution (for clinical trial use only)', 'Protocol version:', 'Version 2.2', 'Date:', '10 September 2019', 'Sponsor:', 'Cara Therapeutics, Inc.', '4 Stamford Plaza', 'Stamford, CT 06902', '(203)406-3700', 'Information contained in this document is proprietary and confidential information of Cara Therapeutics,', 'Inc. Any distribution, copying, or disclosure is strictly prohibited unless such disclosure is required by', 'federal regulations or state law. Persons receiving the information in this document are hereby given notice', 'that the information is confidential and may not be further copied, distributed, disseminated or otherwise', 'disclosed to any other person without the express written authorization of Cara Therapeutics, Inc.', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 2 of 92', 'CR845-CLIN3103', 'SPONSOR APPROVAL / SIGNATURE PAGE', 'Medical Monitor Name and Contact Information', 'Refer to the Investigator Site File (ISF).', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 3 of 92', 'CR845-CLIN3103', 'INVESTIGATOR APPROVAL STATEMENT', 'I have read and understand the protocol (CR845-CLIN3103) and I agree that this', 'document contains all ethical, legal, and scientific information necessary to conduct this', 'study. I will oversee the conduct of the study as described in the protocol and any', 'amendment(s) made to the protocol.', 'I agree to conduct the study as detailed herein and in compliance with the current', 'International Council for Harmonisation Harmonised Tripartite Guideline for Good', 'Clinical Practice and all applicable regulatory requirements.', 'Principal Investigator (Refer to Investigator Site File [ISF])', 'Printed Name:', 'Signature:', 'Date:', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}